KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Issued
Ratios

Regeneron Pharmaceuticals (REGN) Receivables - Net (2016 - 2025)

Regeneron Pharmaceuticals has reported Receivables - Net over the past 17 years, most recently at $5.7 billion for Q4 2025.

  • Quarterly results put Receivables - Net at $5.7 billion for Q4 2025, down 7.58% from a year ago — trailing twelve months through Dec 2025 was $5.7 billion (down 7.58% YoY), and the annual figure for FY2025 was $5.7 billion, down 7.58%.
  • Receivables - Net for Q4 2025 was $5.7 billion at Regeneron Pharmaceuticals, up from $5.7 billion in the prior quarter.
  • Over the last five years, Receivables - Net for REGN hit a ceiling of $7.0 billion in Q2 2021 and a floor of $4.2 billion in Q1 2021.
  • Median Receivables - Net over the past 5 years was $5.6 billion (2023), compared with a mean of $5.5 billion.
  • Biggest five-year swings in Receivables - Net: skyrocketed 1021.35% in 2021 and later fell 26.25% in 2022.
  • Regeneron Pharmaceuticals' Receivables - Net stood at $6.0 billion in 2021, then fell by 11.73% to $5.3 billion in 2022, then rose by 6.35% to $5.7 billion in 2023, then rose by 9.61% to $6.2 billion in 2024, then fell by 7.58% to $5.7 billion in 2025.
  • The last three reported values for Receivables - Net were $5.7 billion (Q4 2025), $5.7 billion (Q3 2025), and $5.6 billion (Q2 2025) per Business Quant data.